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Abstract 
The current issues surrounding the use of genetic profiling technologies in New Zealand are analysed 
and compared with other jurisdictions, resulting in a number of key recommendations for the legal 
framework. An amendment to the Human Rights Act, review of the Health Information Privacy Code 
and an increased role for the Insurance and Savings Ombudsman are discussed in light of the 
developments in other jurisdictions. The implementation of a genetic database registration system and 
the development of policies to guide employers, insurers and health professionals on acceptable uses of 
genetic profile information are presented as recommendations to improve the current approaches. The 
establishment of an Advisory Body would ensure that safeguards against discrimination continue to be 
fair and effective, keeping pace with the rapid advancements in this field. The increased availability 
and the more acceptable costing are making the use of genetic profiling technology attractive. This is 
contributing further to the legal challenges, particularly when combined with the increasing range of 
applications for the data provided, in such diverse fields as the insurance industry, employment, 
personalised pharmaceuticals and the use of genetic databases. It is seen as essential that the legal 
framework promotes and supports the public in their access and use of genetic profiling technologies. 
These developments promise to be important and at the forefront of future heath care in New Zealand.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic Profiling: A Legal Framework to Embrace the Challenges 
 
 
3 
Table of Contents 
I Introduction ........................................................................................... 4 
II Background – Genetic Profiling and Discrimination  ........................... 5 
III Implications for Insurance  ................................................................. 6 
A New Zealand Law ...................................................................................... 7 
B Comparative Approaches ........................................................................... 9 
1 Legislative Approaches ................................................................... 9 
2 Voluntary Moratorium ....................................................................10 
3 Critique ..........................................................................................12 
C Recommendations for New Zealand ..........................................................12 
IV Implications for Employment............................................................. 14 
A New Zealand Law .....................................................................................15 
B Comparative Approaches ..........................................................................18 
1 Prohibition of Use  .........................................................................19 
2 Permission Subject to Exceptions  ..................................................20 
3 Critique ..........................................................................................23 
C Recommendations for New Zealand ..........................................................24 
V Genetic Databases .............................................................................. 26 
A New Zealand Law .....................................................................................28 
B Comparative Approaches ..........................................................................30 
C Recommendations for New Zealand ..........................................................31 
VI Disclosure to Relatives ...................................................................... 33 
A New Zealand Law .....................................................................................34 
B Comparative Approaches ..........................................................................36 
C Recommendations for New Zealand ..........................................................38 
VII Pharmacogenetics ............................................................................ 39 
VIII Embracing the Challenges .............................................................. 42 
IX Conclusion ........................................................................................ 43 
X Bibliography ....................................................................................... 46 
 
 
 
 
 
Genetic Profiling: A Legal Framework to Embrace the Challenges 
 
 
4 
I Introduction 
 
Recent technological advances have resulted in much greater knowledge about genes 
and an increased ability to test for genetic diseases. The private nature and availability 
of information revealed by these tests increases the risk of discrimination, with 
predictable consequences for insurance and employment, wider privacy issues such as 
the storage of information in Deoxyribonucleic Acid (DNA) Banks and the disclosure 
of information to related individuals, along with implications arising from 
pharmacogenetic testing.  
 
Identifying DNA mutations, changes to the chromosome number or protein 
abnormalities linked to a genetic disease can confirm or eliminate a suspected disease, 
but can also determine the likelihood of developing or passing on a disease.1 The 
public health system currently provides routine testing and counselling for individuals 
with a family history of genetic diseases, such as breast cancer and neurological 
conditions.
2
 With the cost of some diagnostic procedures being reduced commercially 
to less than 200 dollars, these technologies are becoming increasingly accessible.3 
Some tests, such as for the diagnosis of Huntington’s Disease, can involve reasonably 
accurate predictions, but those that can reveal predispositions may be influenced by 
environmental and lifestyle factors leading to incorrect conclusions about the 
potential risk.4  Professor Richard Faull, Director of the University of Auckland’s 
Centre for Brain Research, believes that current research will lead to “packages of 
care tailored to patients’ specific needs.”5 The trend towards personalised medicine is 
likely to include genome profiling and underpin future healthcare options, giving rise 
to contentious debate about the access to personal information.6  
 
This paper analyses the different regulations and policy surrounding the use of 
information arising from genetic profiling, leading to the conclusion that it is 
necessary to review the current approaches in New Zealand. This would enable 
clarification of the ambiguities and ensure that there are sufficient safeguards in place, 
particularly in light of the implications for access to the rapid advances in medical 
technology and the range of treatments.  
 
 
                                                        
1  US National Library of Medicine “What is Genetic Testing” (1 July 2013) Genetics Home 
Reference<ghr.nlm.nih.gov>.  
2 Nikki Macdonald “Unveiling Your Genetic Compass” (13 April 2013) <www.stuff.co.nz>. 
3 Macdonald, above n 2. 
4 Macdonald, above n 2. 
5 Phil Taylor “Unlocking the Secrets of Our Brains” The New Zealand Herald (New Zealand, 07 
September 2013) at A22. 
6 Nikki Macdonald “Unveiling Your Genetic Compass” (13 April 2013) <www.stuff.co.nz>. 
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II Background – Genetic Profiling and Discrimination 
 
All sources of medical information including that available from medical records, 
family history or as has only recently become possible, through more accurate and 
comprehensive genetic profiling, can lead to discrimination. A 1998 United Kingdom 
survey provided evidence further supporting the view that discrimination was a reality 
in the context of the insurance industry.7 Prior to the introduction of the 2008 anti-
discrimination law in the United States, a significant number of cases of genetic 
information adversely affecting insurance or resulting in job losses were documented 
by the Council for Responsible Genetics.8  
 
The two competing jurisprudential theories about genetic discrimination are that 
discrimination is acceptable because it enhances efficiency, as in the formulation of 
insurance ratings, with the opposing view being that it disadvantages individuals in 
unavoidable personal circumstances, hence challenging equality principles.9 “Genetic 
exceptionalism” underpins these competing considerations, arguing that genetic 
information is a distinct health information class because it is familial (hence may 
reveal information about relatives without their consent) and as the genetic code is 
“fixed and unchangeable,” it is outside an individual’s control.
10
 Some argue that 
genetic information is no different from other health related information and therefore 
should be treated as falling under the relevant privacy and anti-discrimination law.11    
 
The United Nations endorsement of the Universal Declaration on the Human Genome 
and Human Rights 1998 (UDHGHR) has a key principle of respect for human dignity, 
including a general prohibition on discrimination based on genetic characteristics.12 
The Office of the United Nations Commissioner for Human Rights developed an ad 
hoc expert committee in 2002, to consider priorities regarding human rights due to 
biotechnological advances, identifying discrimination as a key issue.13  
 
The General Conference of the United Nations Educational, Scientific and Cultural 
Organisation adopted the Universal Declaration on Human Genetic Data (UDHGD) 
in 2003, reflecting the 1998 Declaration and highlighting the complex nature of 
                                                        
7 Lowrence Low, Suzanne King and Tom Wilkie “Genetic discrimination in Life Insurance: Empirical 
Evidence from a Cross Sectional Survey of Genetic Support Groups in the United Kingdom” (1998) 
317 British Medical Journal 1363. 
8 Council for Responsible Genetics “Genetic Testing, Privacy and Discrimination” 
<www.councilforresponsiblegenetics.org>.  
9 Alexander Somek “Genetic Discrimination” (2003) 40 Society 35 at 37. 
10 Jennifer Molina “Genetic Privacy: Issues in Aotearoa/ New Zealand” (Summer Studentship, Social 
Science Research Centre, University of Canterbury, 2005) at 9. 
11 At 10. 
12 Universal Declaration on the Human Genome and Human Rights A/Res/53/152 (1998), arts 1, 6. 
13 Report of the Expert Consultation on Human Rights and Biotechnology (Geneva 2002) at [2].  
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genetic information due to environmental, social and cultural factors.14 The UDHGD 
emphasises the concept of non-discrimination and non-stigmatisation and is intended 
to guide countries formulating legislation and policies underpinned by respect for 
human dignity.15 
 
III Implications for Insurance 
 
An insurance company collects premium payments from a group and uses this to pay 
those in the group who make a claim, therefore spreading the financial loss for one 
individual across the group.16 Consequently, the premium for an individual is based 
on the likelihood of a claim being made by assessing risk factors such as age, health, 
sex and family history, using worldwide statistics.17 This means that it is inevitable 
that insurance providers will want to adjust their rates according to new information, 
such as a predisposition to a disease, obtained by genetic profiling.18  
 
The claim that discrimination is acceptable is based on the argument that using this 
information means a more accurate assessment of risk for the insured and therefore 
fairer insurance policies for those who have lower risks in that insurance pool.19 This 
is in the interests of the insurer and those being insured, therefore arguably justifiable 
as it results in premiums that more accurately reflect the potential loss of the insured 
person.20 A basic principle of insurance is equality of access to relevant information 
between the insurer and the insured.21 If insurers did not have the right of access to 
this information then they would be less able to accurately determine risks and predict 
the money needed to cater for losses, further challenged by the fact that individuals 
who know their own high risk due to genetic profiling will seek an increased amount 
of insurance.22 This is commonly referred to as adverse selection because it allows 
high risk individuals to take advantage of the market due to unequal access to 
information and gain insurance benefits below an appropriate cost that are effectively 
subsidised by the rest of the insurance pool.23 Low risk individuals may also seek 
little or no insurance, leading to an insufficient insurance pool and market collapse.24  
                                                        
14 International Declaration on Human Genetic Data, (32 C/Res 22), arts 3, 4. 
15 Article 7. 
16  Human Rights Commission Guidelines: Insurance and the Human Rights Act 1993 (November 
2007) at 5. 
17 At 5. 
18 Somek “Genetic Discrimination”, above n 9, at 36. 
19 At 37. 
20 At 37. 
21 At 37. 
22 At 37. 
23 Andru Isac “Latent Defects in Human Capital: Regulating Genetic Testing and the Insurance Market”  
(2003) 9 NZBLQ 315 at 318. 
24 At 318. 
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Compulsory genetic profiling could provide a solution to this problem by enabling 
more accurate classification of risks.
25
 Insurance provides protection from 
unpredictable events and it is unreasonable to restrict insurers from taking into 
account increasingly predictable risks. 26  
 
The argument against discrimination is that it would be “manifestly unfair” because 
there is nothing that an individual can do to avoid a predisposition which is “inherited 
and immutable”.27 A further consideration is the risk of genetic information being 
used in an uninformed way. Distinction needs to be made between monogenic 
disorders such as Huntington’s Disease (whereby onset is inevitable) and complex 
polygenic disorder predispositions (whereby the likelihood and seriousness of any 
disease is much more uncertain).28  Uninformed use of data has been revealed in 
studies such as one Australian case, which involved a 22 year old woman who tested 
positive for a predisposition to bowel cancer and was subsequently declined travel 
insurance.
29
 Genetic discrimination may discourage individuals from having 
necessary medical tests, in order to avoid compromising the financial position of the 
entire family. 30  The heritable nature means that diagnosis of one individual has 
implications for an entire family who may be at risk of “red flagging by insurers”.
31
 
 
A New Zealand Law 
 
Human rights are protected in New Zealand by a legislative regime including the New 
Zealand Bill of Rights Act (BORA), Human Rights Act (HRA), Health and Disability 
Commissioner Act 1994 (HDCA) and the Privacy Act 1993.32 BORA, HRA and the 
HDCA all make it unlawful to discriminate on certain prohibited grounds including a 
disability, but it is unclear whether the definition of a disability would include a 
genetic predisposition.33 The adequacy of the existing framework depends on New 
Zealand’s view of “genetic exceptionalism” (due to the familial nature and lack of 
individual control as discussed above) or whether genetic information can be “lumped 
together” with general health information.34   
 
                                                        
25 Somek “Genetic Discrimination”, above n 9, at 37. 
26 Michael Kinsley “Genetic Discrimination: Unfair or Natural?” (2008) <www.time.com>.  
27 Isac, above n 23, at 319. 
28 At 317.  
29 At 317. 
30 At 318. 
31 At 316. 
32  Human Rights Commission Human Rights in New Zealand Today: Biotechnology and the 
Developments Arising from the Study of the Human Genome (2004) at ch 19. 
33 At ch 19. 
34 Mark Henaghan and others The Regulatory Implications of the Human Genome Project for New 
Zealand: Phase 1 (Human Genome Research Project, Dunedin 2003) at 9. 
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The National Health Advisory Committee on Health and Disabilities produced a 
report on Molecular Genetic Testing in New Zealand (2003), acknowledging the 
“social and ethical issues in genetic testing and the implications for insurance and 
employment” but did not explore this in any depth.35 The Human Rights Commission 
Report in 2004 found that in order to comply with its international obligations, New 
Zealand needed to ensure non-discrimination by considering the effectiveness of the 
HRA and BORA in preventing genetic discrimination within the insurance industry 
and whether legislative amendment was necessary.36 The Bioethics Council and an 
independent study undertaken by Otago University (which considered the 
consequences of the human genome project for New Zealand) led the investigation 
into the implications of genetic profiling. 
 
New Zealand has not enacted legislation in response to this issue. The insurance 
industry is governed by a self-imposed voluntary moratorium (through the Investment 
Savings and Insurance Association (IAI)) preventing an insurer requesting a genetic 
profile.37 However, where a genetic profile has already been undertaken, the insurer 
can request that information and disclosure is required of the insured person.38  
 
Section 19 of the BORA provides the right to be free from discrimination under the 
prohibited grounds of discrimination set out in s 21 of the HRA, including sex, 
religion, age and disability, among others.39 Section 44 of the HRA makes it unlawful 
to discriminate in the provision of goods and services and “facilities by way of 
insurance” and therefore insurers cannot refuse to provide insurance or treat them less 
favourably by reason of any of the prohibited grounds of discrimination (both directly 
and indirectly) in s 21.40  As insurance is about classification of risk, there is an 
exception in s 48 that allows distinctions on the grounds of sex, disability and age, 
based on actuarial data.41 There is no provision prohibiting discrimination by insurers 
on the grounds of genetic profile results and even if this is included under the 
definition of disability (which has not yet been considered by the courts), s 48 would 
allow an exception, therefore the HRA does not prevent discrimination on the grounds 
of genetic information. 
 
                                                        
35 Molecular Genetic Testing in New Zealand (National Health Advisory Committee on Health and 
Disabilities, October 2003) at 9. 
36 Human Rights Commission, above n 32, at ch 19. 
37 Human Rights Commission, above n 16, at 14. 
38  Human Rights Commission Discussion Paper: Review of the Guidelines on Insurance and the 
Human Rights Act 1993 (2006) at 13, 14. 
39 New Zealand Bill of Rights Act, s 19; Human Rights Act, s 21. 
40 Sections 44, 65. 
41 Section 48; Human Rights Commission, above n 16, at 5. 
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The Human Rights Commission published Guidelines on Insurance and the HRA in 
1997 to assist the industry and the public in understanding how human rights relate to 
insurance but did not address the issue of genetic information.42 A 2007 review of 
these guidelines was conducted in response to issues such as the increasing 
availability of genetic profiling. The review noted that the current self imposed 
moratorium approach is consistent with adverse selection concerns because it 
recognises the need for insurers to have access to the same information about an 
applicant’s health as the actual applicant, although there is uncertainty about whether 
this is a realistic concern.43 However, the need to balance discrimination based on 
genetic status to avoid excessive premiums or exclusion from insurance was also 
highlighted.44 The review questioned the current approach, noting the flexibility and 
ease of implementation but also its non binding and voluntary nature, raising the idea 
of changes to the legislation, such as the inclusion of genetic status as a prohibited 
ground under the HRA or (as in the United States) by a completely separate piece of 
legislation.
45
  
 
Feedback was generally positive, with the New Zealand Society of Actuaries and the 
Medical Assurance Society recommending that the current moratorium be 
compulsory for all insurance companies but also that there should be a review as 
genetic profiling increases. 46  The Mental Health Foundation raised the issue of 
discrimination linked to genetic profiling for existing or possible future development 
of mental illness. 47  While the moratorium is currently seen as effective in New 
Zealand, the Human Rights Commission believes there is an opportunity to monitor 
international best practice development and promote debate of future options.48 
 
B Comparative Approaches 
 
1 Legislative Approaches 
 
Countries that have introduced regulation restricting the use of genetic profile 
information in insurance through either privacy legislation or antidiscrimination laws 
                                                        
42 Human Rights Commission, above n 16, at 7. 
43 At 13, 14. 
44 At 13. 
45 Human Rights Commission, above n 38, at 4. 
46 New Zealand Society of Actuaries Submission to the Human Rights Commission on the Review of 
the Guidelines on Insurance and the Human Rights Act 1993 Discussion Paper (2006) at 6. 
47 Mental Health Foundation of New Zealand Submission to the Human Rights Commission on the 
Discussion Paper: Review of the Guidelines on Insurance and the Human Rights Act 1993 (2006) at 3. 
48 Human Rights Commission, above n 16, at 14. 
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generally focus on whether genetic profiling can be compulsory and whether an 
applicant can be required to disclose genetic test results for risk analysis.
49
  
 
The United States and some European Countries have taken the approach of 
prohibiting insurers from requesting genetic profile information, generally under the 
right to privacy.50 The European Convention on Human Rights and Biomedicine 1997 
prohibits “any form of discrimination against a person on the grounds of his or her 
genetic heritage”.51 Austria, Belgium and Norway are countries that have acted to 
implement this convention but with the exception of Austria, this is rarely addressed 
in one consolidated statute.
52
  
 
The United States passed the Genetic Information Non-Discrimination Act (GINA) in 
2008 to prohibit the requirement of genetic tests and prevent discrimination in 
insurance coverage or premium costs (or employment) based on genetic profile 
results.
53
 This was seen by the National Human Genome Research Institute as 
necessary for biomedical research and personalised medicine to advance,54 but this 
legislative measure does not extend to cover life or long term care insurance which is 
already creating problems for some who have undergone genetic profiling.
55
 The 
difficulty of using anti-discriminatory laws is that insurance markets have been 
traditionally predicated on the ability of insurers to rationally discriminate between 
individuals based on their own risk.56 There is confusion over the definition of genetic 
information and genetic profiling in some countries, such as Austria, Israel and 
Denmark, where legislative prohibition prevents insurers from seeking genetic 
information.57 
 
2 Voluntary Moratorium  
 
The United Kingdom currently relies on a voluntary moratorium similar to that in 
New Zealand. However the United Kingdom approach involves a compromise 
moratorium allowing applicants to refuse to reveal information if the policy is below a 
                                                        
49 Isac, above n 23, at 319. 
50 Human Rights Commission, above n 38, at 13. 
51 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the 
application of Biology and Medicine: Convention on Human Rights and Biomedicine CETS 164 
(opened for signature 4 April 1997, entered into force 1 December 1999), art 11. 
52 Isac, above n 23, at 319, 320. 
53 Section 1. 
54 David Resnick “A Big Step Toward Personalised Medicine” (2008) <www.masshightech.com>.  
55  Rob Stein “Scientists See Upside and Downside of Sequencing their own Genes” (2012) 
<www.npr.org>.  
56 Isac, above n 23, at 316. 
57 Human Rights Commission, above n 16, at 14. 
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certain amount.58 One recommendation by the Human Genetics Commission was that 
the United Kingdom legislation incorporate the principle that “we affirm that humans 
are born equal, that they are entitled to equality of opportunity and that neither genetic 
constitution nor genetic knowledge should limit that equality”. 59  The British 
Insurance Industry argument is that insurance operates to benefit everybody by 
balancing its ability to assess risk on the basis of all relevant information while not 
discouraging testing due to fear of eligibility or costs.
60
 The Genetics and Insurance 
Committee was set up in 1999 as an independent review body to ensure that genetic 
information for insurance purposes is used only where relevant and supported by 
scientific and actuarial evidence.
61
 
 
While Australia also has a voluntary moratorium, it is only in the context of life 
insurance. 62  The Australian Law Reform Commission and the Australian Health 
Ethics Committee of the National Health and Medical Research Council published a 
Report in 2004 “Essentially Yours”, following a comprehensive inquiry into 
Australia’s regulatory framework.63 Recommendations were wide in scope, dealing 
with privacy (disclosing information to relatives), ethical oversight of research, 
discrimination by employers and insurance, DNA data sharing, along with many other 
issues and included the establishment of a Human Genetics Advisory Committee 
(HGAC) to advise the government.64 Following this, “disability” was redefined in the 
Disability Discrimination Act 1992 (Cth) (DDA) to include a disability that may arise 
due to a genetic predisposition.65 The Report also recommended that the Investment 
and Financial Services Association improve the underwriting process to include 
scientific reliability (the link between the mutation and the expression of the disease) 
and its actuarial relevance (the link between the expression of the disease and 
increased morbidity or mortality). This has been implemented by introducing policy 
standards, the increased training of underwriters and the establishment of an 
independent body by the HGAC, to ensure the reliability of the data.66  
 
 
                                                        
58 HM Government “Concordat and Moratorium on Genetics and Insurance” (2011) <www.gov.uk>; 
Human Rights Commission, above n 16, at 13, 14. 
59 Molina, above n 10, at 12. 
60 At 12, 13. 
61 Wellcometrust “The Genetics and Insurance Committee” The Human Genome 
<www.welcome.ac.uk>.  
62 Mark Henaghan and others Genes Society and the Future Volume 3 (Human Genome Research 
Project, Dunedin 2009) at 345. 
63 Australian Law Commission and the National Health and Medical Research Council Essentially 
Yours: The Protection of Human Genetic Information in Australia (ALRC Report 96) (30 May 2003). 
64 Australian Law Reform Commission Protection of Human Genetic Information (19 July 2012). 
65 Australian Law Reform Commission, above n 64; Section 4(j). 
66 Australian Law Reform Commission, above n 64. 
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3 Critique 
 
Regulatory models based on privacy laws confirm genetic exceptionalism. An 
opposing argument is that the current disclosure of family health history and general 
medical information is no different from genetic information.67 In addition, privacy 
based laws cannot be reconciled with the fundamental common law duty of disclosure 
which ensures insurance contracts achieve the equality of access underpinning the 
establishment of insurance premiums.68  
 
A model based on antidiscrimination is also contradictory because insurance is based 
on the ability of an insurer to use discrimination for effective pricing.69 As noted, 
discrimination already occurs using family history and non-genetic tests to indicate 
the likelihood of getting a disease or suffering from adverse health.70 An exception 
banning discrimination based on genetic information that is supported by actuarial 
data may be difficult to justify.
71
 
 
D Recommendations for New Zealand 
 
Due to the complex, uncertain nature of genetic information and the potential impact 
it can have on insurance accessibility, this paper argues that the present approach in 
New Zealand is inadequate. If the moratorium is retained, legislation making this 
compulsory needs to be initiated along with a mechanism for enforcing compliance.  
 
Whether or not the current approaches in New Zealand are able to adequately provide 
actuarial data for genetic information is one question raised by the New Zealand Law 
Commission and also referred to in the Human Rights Commission discussion 
paper. 72  Following the Australian approach of implementing an independent 
regulatory body to rule on such decisions could be an effective means of monitoring 
and avoiding the creation of a disincentive against using genetic profiling 
technologies. Increased training for insurance providers about the implications of 
profiling would be beneficial. 
 
If genetic status discrimination is to be dealt with under the HRA antidiscrimination 
law, this paper recommends that a distinction is made between pre-symptomatic 
disabilities and the pre-disposition genetic conditions with the potential to be 
                                                        
67 Isac, above n 23, at 324. 
68 At 324. 
69 At 324. 
70 At 324. 
71 At 324. 
72 Human Rights Commission, above n 38, at 14. 
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influenced by environmental conditions and lifestyle choices.73 If genetic status is 
included in the HRA legislation, this may have further implications for other areas 
that are covered by the Act resulting in broader policy questions that need to be 
addressed.  
 
It would also be useful to reconsider the role of the Insurance and Savings 
Ombudsman (ISO) in receiving complaints about discrimination based on genetic 
profiling. This would be binding on the participants of the ISO scheme and therefore 
could be one mechanism for providing a complaints system that is free for consumers, 
prior to the expensive exercise and time consuming exercise of pursuing litigation in 
the courts.74 However there would need to be changes to the ISO responsibilities, as 
current procedures would not be permit complaints to include issues about 
discrimination leading to higher premiums or consider underwriting decisions and 
whether the insurer had used the information in an unfair way.75  One possibility 
would be to expand the role of the ISO, to enable consideration of discrimination and 
inappropriate use of genetic information. It would be necessary to increase public 
awareness of any changes to the complaints process. 
 
This paper proposes that it would also be useful to establish an Advisory Body similar 
to that in Australia to review the approaches taken in other jurisdictions and monitor 
the developments in New Zealand. This would be assisted by including genetic status 
as a prohibited ground of discrimination, given that the social implications of using 
genetic information in other areas are significant, such as in employment discussed 
below. 
 
This section has focused on the issues that have arisen in the insurance industry, 
analysing the different regulatory approaches to genetic privacy and leading to the 
conclusion that New Zealand’s current approach of a voluntary moratorium needs to 
be reviewed. This is supported by the underlying argument that law and policy needs 
to encourage access to new technologies, such as genetic profiling, by ensuring that 
the public can be confident in their expectation that there are adequate safeguards in 
place to protect individuals against any potentially negative consequences.  
 
 
 
                                                        
73 At 14. 
74  Insurance and Savings Ombudsman “complaints the ISO can Consider” ISO 
<www.iombudsman.org.nz>.   
75 Insurance and Savings Ombudsman, above n 74.  
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IV Implications for Employment 
 
Allowing employers to discriminate on the basis of genetic profiling may be valid on 
economic, health and safety grounds but balancing these against the autonomy of the 
employee or applicant is seen as essential. Employment decisions may inevitably 
involve some discrimination on such grounds as education, previous work experience, 
personality and in today’s environment, increasingly psychometric testing.76 Genetic 
profiling could allow employers to recruit with more certainty and to avoid the costs 
associated with employees who are likely to become ill, require leave or need to be 
replaced due to poor health. Genetic profiles could be used for health and safety 
concerns such as may arise, for example when the test results for a pilot revealed an 
increased risk of heart attack. Legal restrictions may be necessary to prevent 
employers seeking to exclude individuals from the workplace considered to have an 
unfavourable genetic profile. 77 
 
Decisions based on genetic information can also lead to employment discrimination 
on the grounds of race, sex or disability.78  If an employer refuses to employ an 
applicant due to a genetic disposition to a disease associated with the female gender, 
such as breast cancer, this could be perceived as sexual discrimination. Where there is 
a strong link between a genetic disposition and a particular population group, such as 
the disease sickle cell anaemia link with Afro-Caribbean discussed below, refusing to 
employ people belonging to that group could amount to racial discrimination.79 If a 
genetic condition is likely to develop into a disease, it may also lead to different 
employment conditions amounting to disability discrimination.
80
  
 
Genetic profiling in the workplace could involve control and coercion by the 
employer, as they can be used to refuse an applicant, dismiss an employee or demote 
them to a different job as a consequence.81 In addition, privacy and other issues may 
arise if health details are used inappropriately or disclosed to other parties and 
emotional and psychological distress may occur from test results that indicate the 
problem is significant.82  The Human Rights Commission reported that the use of 
information from genetic profiling did not appear to be a current factor in 
                                                        
76  James Desmond K Gardner-Hopkins "Unemployable Genes: Genetic Discrimination in the 
Workplace" (2001) 9 Auckland UL Rev 433 at 347. 
77 At 348. 
78 Human Rights Commission, above n 32, at ch 19. 
79 At ch 19. 
80  Phillipa Gannon and Charlotte Villiers “Genetic Testing and Employee Protection” (1999) 4 
MedicalLInt 39 at 44. 
81 At 40. 
82 At 40. 
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employment disputes.83 However concerns were raised that it may be used in future 
recruitment decisions, and that there was a need to protect third parties with respect to 
occupational health and safety matters.  
 
A New Zealand Law 
 
The BORA, s 19 includes the right to be free from discrimination on the grounds set 
out in the HRA.84  Section 21 (HRA) prohibits discrimination on the grounds of 
disability, race and sex and s 22 makes it unlawful for an employer to refuse or 
terminate employment or offer less favourable terms by reason of any of the 
prohibited grounds of discrimination.85 Under s 23 it is unlawful to make an inquiry 
about an applicant for employment, which could be reasonably understood to indicate 
any intention to commit a breach of s 22. 86  An exception to the prohibition of 
discrimination against people with disabilities set out in s 22 is provided in s 29, 
where the person could only perform the duties satisfactorily with the aid of special 
services or facilities which it would not be reasonable to expect of the employer, or 
that the work conditions mean a possible risk of harm to themselves or a third party.87 
This is subject to s 29(2) that the employer could not, without reasonable disruption, 
take measures to reduce the risk to an acceptable level.88 The Employment Relations 
Act 2000 provides that an employee who has been discriminated against during 
employment may pursue personal grievance, 89  with the prohibited grounds of 
discrimination being those provided for in s 21 of the HRA (above) and exceptions in 
s 29 (above),
90
 unless justified on the grounds of being fair and reasonable actions.
91
  
 
The HRA provisions have been described as problematic in relation to genetic 
discrimination in employment for several reasons. In the first instance, it is 
ambiguous as to whether the definition of “disability” as provided in s 21 would be 
wide enough to include discrimination on the ground of genetic pre-disposition 
(discussed in Part III with respect to insurance).92 If it does, s 22 would therefore 
include the prohibition of discrimination against an employee or applicant on the 
grounds of their genetic predisposition and s 23 would appear to prohibit the 
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requirement that an applicant undergo genetic profiling.93 However the exception in s 
29 creates ambiguity in relation to those genetic profile results that reveal an 
increased likelihood of harmful effects from exposure to workplace toxins.94 Whether 
or not this is discrimination would depend on the interpretation by the court of 
“reasonable” in s 29. It has been suggested that this use of genetic profiling would be 
interpreted as being similar to the current practice of physical stress tests to determine 
likelihood of contracting asthma from exposure to substances in a workplace.
95
 
 
The Health and Safety in Employment Act 1992 intersects with the HRA. Section 6 
imposes a duty on employers to be responsible for providing a safe work environment 
for their employees and s 15 provides that the employer must take all practicable steps 
to ensure that the employee does not harm any other person who is not an employee.96 
“All practicable steps” are defined as “all steps to achieve the result that it is 
reasonably practicable to take in the circumstances”, having regard to what is known 
about the severity, likelihood, financial constraints, effectiveness and availability of 
means to address the potential harm.97 The Human Rights Commission indicated that 
it is conceivable that this responsibility could extend to using genetic profiling for the 
identification of employees susceptible to work place hazards or who create a danger 
to others.98 It is likely that the outcome would again depend on the interpretation of 
“reasonably practicable” by the court.99 It is even possible that the requirement of a 
genetic test to determine the risk of harm from workplace toxins may be required of 
an applicant or employee as part of the “all practicable steps” provision, should 
profiling be considered to be information that “ought reasonably” be known by the 
employer, as access to this technology increases.100  
 
The lack of clarity in the law has the possibility of resulting in two less than desirable 
outcomes. Employers may find themselves caught between the requirement of “all 
practicable steps” to protect the health of employees, on the one hand, and the 
prohibition against discrimination on the basis of disability, on the other. 101 
Employees or potential employees may find themselves required to provide a genetic 
profile as a precondition of employment or before undertaking particular tasks, 
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perhaps as a result of an employer endeavouring to take “all practicable steps”.102 
While this may be seen as a positive step towards improving workplace health and 
safety, the concerns discussed in the beginning of this section would be contentious. 
Issues such as the sensitive and predictive nature of this information, the potential 
implications for family members, as for insurance, sit alongside the ultimate 
consequence that the individual may be left without employment. 103  The other 
concern, similar to that highlighted with respect to insurers in part III, is that 
employers may misinterpret the genetic information. There is potential for misuse by 
assuming that the result means a definitive conclusion about the likelihood of an 
individual developing a disease. Further, genetic profiling may shift the focus away 
from improvements that would make the workplace safer for everyone, toward 
ignoring a problem through the removal of particularly susceptible workers.104 
 
In New Zealand, the Accident Compensation Corporation (ACC) policies are also 
likely to be relevant in relation to the practice of genetic profiling in employment as 
the ACC provides cover for “‘personal injury caused by work-related gradual process, 
disease, or infection”.105 Of significance to the ACC is geno-toxicological testing, a 
type of genetic profiling that targets genetic variation associated with greater or lesser 
susceptibility to harm from exposure to known toxins.106 Genetic profiling was not 
mentioned in the Workplace Health and Safety Strategy for New Zealand to 2015, 
published by the Department of Labour in 2005.107 It appears that the ACC has not 
considered that results could potentially be used as evidence of a link between the 
illness and exposure by employers claiming accident compensation, or alternatively 
tests could be required by the ACC to dispute a link.108 It could argued that the ACC 
system means that employers in New Zealand have little incentive to use genetic 
profiling to screen employees as ACC compensates and rehabilitates injured 
workers.109 
 
However there is still scope for genetic profiling as some employers already use 
medical screening in ways that parallel the potential use of genetic profiles (such as 
with the exposure example above) and could be seen as another step on the 
continuum.110 Further, at least 25 per cent of employees in New Zealand currently 
work for employers who have opted through the ACC Accredited Employer 
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Programme to self-insure for workplace injury and illness.111 The Programme allows 
the employer to act on behalf of the ACC for an employee’s work related injuries, 
which would negate the ACC considerations with respect to gene profiling and 
employment.112  
 
B Comparative Approaches 
 
Although there is little evidence of genetic profiling in New Zealand workplace, there 
are numerous examples in other jurisdictions. In the 1970s, carriers of the sickle cell 
disease, present in seven per cent of Africans but less than one per cent of Europeans, 
were unnecessarily excluded from a number of occupations as it was believed they 
may be adversely affected by certain chemicals.113 In the United States, this led to 
screening programs to identify carriers of the gene as illustrated by the screening 
currently used to sort applicants for aircrew training in both the British and American 
military due to the serious health risks faced by carriers at high altitudes.
114
 
 
The United States history of workplace discrimination from the use of genetic 
information is highlighted by the 2013 lawsuit, Equal Employment Opportunity 
Commission v Fabricut Inc, which sought to enforce genetic non-discrimination rights 
under Title II of GINA 2008.115 Following a pre-employment medical examination, 
Fabricut required an applicant for a clerk position to obtain additional testing to rule 
out Carpal Tunnel Syndrome (CTS), after initially offering the appointment.116 The 
testing ruled out CTS but Fabricut still withdrew the job offer on the grounds of the 
medical examination and the company view that the applicant had CTS.117 Damages 
of United States $50, 000 were agreed to by the company along with an undertaking 
to take corrective action that included a non-discrimination notice to employees 
(required by GINA) and non-discrimination training for all staff involved in hiring 
decisions.118  
 
In Australia, widespread problems associated with employers misusing genetic 
information have not been reported but this does not necessarily rule out 
discrimination. The fear of victimisation following the lodging of a complaint is a real 
issue which is compounded by people being unaware of their rights. A 2003 review 
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found considerable uncertainty about the nature and extent of discrimination in 
employment but at the time, was awaiting the empirical research being undertaken by 
the Genetic Discrimination Project Team.119  
 
As early as 2001, an Australian study into genetic discrimination did identify 
situations where genetic profiling was required as a pre-requisite of employment and 
examples of discrimination against asymptomatic employees.
120
 An illustration of this 
is the situation in which a young woman applicant for a public service position was 
informed that a negative genetic profile result for familial adenomatous polyposis was 
to be a condition of her employment because regular colonoscopies for early signs of 
bowel cancer suggested to the employer that she was in fact, at risk of the disease.121 
As the test results came back positive, the applicant did not proceed with her job 
application.122  
 
1 Prohibition of Use 
 
Some jurisdictions have addressed the potential impact of genetic profiling in the 
context of employment by legislating against the use of genetic information. This has 
been in the form of either complete or partial prohibitions with specific exceptions for 
third party safety or to protect an employee. The European Convention on Human 
Rights and Biomedicine could be interpreted to mean that workplace testing will only 
be acceptable if it is to benefit the health of the employee.123 The accompanying 
explanation states that genetic profiling by insurers or employers offers no health 
benefit to the individual and therefore is an invasion of privacy that will only be 
permitted on the grounds of the interests of third parties or the wider public good. 
 
The examples of total prohibition on the use of genetic information seen in Austria, 
France and Norway are confined to genetic profile results and exclude family medical 
history.124 An example is Norway, where it is unlawful for an employer to request or 
use any information derived from a genetic profile.125 The United States has also 
prohibited the use of genetic information in employment with the 2008 enactment of 
the GINA. The position in the United States is complicated by the fact that employers 
usually provide health insurance, consequently employees with medical conditions 
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create higher costs for the employer.126 Title II of GINA focuses on employment, 
protecting individuals from genetic discrimination and banning the use of genetic 
information by employers in hiring decisions.127 
 
Jurisdictions that have prohibitions subject to specific exceptions include the 
Netherlands, Denmark and Israel. 128  These models vary in both the scope of 
exceptions and the type of genetic information covered, although exceptions are 
generally related to the use for occupational health and safety reasons such as 
screening for workplace susceptibilities or conditions that place third parties at risk.129 
 
2 Permission Subject to Exceptions 
 
The current Australian and United Kingdom regulatory frameworks are similar to 
New Zealand. Employers are permitted to collect and use both applicant and 
employee genetic information, subject to limits imposed by occupational health and 
safety, anti-discrimination and privacy legislation.130  
 
The Australian regulatory framework has relevant pieces of legislation. The Human 
Rights and Equal Opportunity Commission Act 1984 (Cth) (HREOC) provides that 
the HREOC may inquire into any practice affecting the equality of opportunity or 
treatment in employment. This is seen as a possible mechanism for reviewing 
discrimination on the basis of genetic status in the future.131 The DDA prohibits an 
employer from discriminating against an applicant on the basis of a disability and the 
“Essentially Yours” Report recommendation that this definition be extended to 
include discrimination on the basis of genetic status, has been implemented.132 The 
employment provisions of the DDA balance the interests of employers, employees 
and the community, acknowledging that it is not unlawful to discriminate if a person 
is unable to carry out the “inherent requirements” of a job because of their disability 
or if it would impose an “unjustifiable hardship” on the employer if required to 
provide such services or facilities.133 The Sex Discrimination Act 1984 (Cth) and the 
Racial Discrimination Act 1975 (Cth) prohibit discrimination in the selection process, 
the terms of employment including training and promotion opportunities and 
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termination conditions, where the genetic information under consideration falls under 
race or gender.
134
  
 
The Australian Workplace Relations Act 1996 (Cth) (WRA) also prohibits 
discrimination on a range of grounds when terminating employment, including race, 
sex and disability, except where they are unable to fulfill the “inherent requirements” 
of a particular position, with the onus on the employer to establish a valid reason for 
dismissal. 135  The Occupational Health and Safety Legislation (present in all 
Australian States and Territories) also overlaps with the antidiscrimination regime 
because employers may use genetic information to assist meeting their obligations 
under the legislation.136 The relationship with the DDA is set out by the HREOC and 
provides that meeting health and safety legislation requirements must be accepted as 
being among the “inherent requirements” of any job.137 
 
Protection from unlawful discrimination is also provided for in several statutes in the 
United Kingdom. The Race Relations Act 1976 and the Sex Discrimination Act 1975 
define discrimination as the treatment of another less favourably on racial or sexual 
grounds.
138
 Both Acts include antidiscrimination provisions in employment covering 
all parts of employment from the application, through to training, transfer or 
dismissal. 139  The Disability Discrimination Act 1995 defines a disability as a 
“physical or mental impairment which has a substantial and long term adverse effect 
on the ability of a person to carry out normal day to day activities”.140 It is unclear 
whether this would include a person with an asymptomatic genetic disorder. Schedule 
1 of the Act may cover a future disorder, as para 8 includes a person who suffers a 
substantial adverse effect where a progressive condition impairs or is likely to impair 
the ability to perform daily activities, suggesting the person must have already 
encountered some difficulty.141  The House of Commons Science and Technology 
Committee suggested that the Act would not be an appropriate means of protection 
against discrimination resulting from genetic profiling.142 
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The United Kingdom Health and Safety at Work etc Act 1974 places a general health 
and safety duty on an employer.
143
 Section 2(2) sets out specific requirements which 
are not directly related to genetic profiling but are relevant as they require the 
employer to take reasonable care to ensure that the systems of work and the articles 
that the employee comes into contact with are safe and do not create any risk to 
health.144 The employer could argue that it is reasonably practicable to reduce the risk 
to health and safety by removing employees that are more susceptible to harm.
145
 An 
employee dismissed may seek remedy for unfair dismissal under the Employment 
Rights Act 1996.146 One of the grounds for dismissal is capability, which is assessed 
by reference to skill, health or any other physical or mental quality.
147
 The health and 
safety obligations of an employer could therefore be used as a reason to exclude the 
employee who has an unfavorable genetic profile.148  
 
An employer may be able to justify discrimination in certain circumstances, such as 
excluding job applicants with the sickle cell trait if the job involved being an air pilot, 
as there are the considerations of public safety and personal harm but it is unclear to 
what extent justifications would be seen as acceptable by the court or tribunal.149 
Page v Freight Hire (Tank Haulage) Ltd shows the combined application of the laws 
concerning discrimination and health and safety, in the context of the removal of a 
woman of child bearing age from a job considered dangerous due to a chemical, 
despite her statement that she did not want to have children and was willing to risk the 
exposure.150 The Court held that the employer had acted in the interests of safety 
under s 2(2)(b) of the Health and Safety at Work Act 1974, emphasising the views of 
the employer rather than the employee, by denying the employee the right to choose 
where to work rather than requiring the employer to change work practices to 
accommodate the employee.
151
  
 
It has been argued that the United Kingdom law is insufficient in its development 
with regard to workplace testing, with some existing rules on discrimination but none 
that are specific to genetics.152 Both the Nuffield Council on Bioethics and the House 
of Commons Science and Technology Committee recommended that genetic profiles 
should only be used where there is strong evidence of a clear connection between the 
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working environment and the disease that the test is seeking to detect.153 It is also 
recommended that the tests should be limited to diseases that seriously endanger the 
health of the employee or present a serious risk to a third party and could not be 
eliminated by the employer taking reasonable measures to modify environmental 
risks.  
 
There was support for legislative action by several advisory bodies in the United 
Kingdom, such as in the 2002 Report of the Human Genetics Commission (the former 
independent advisory body on social and ethical issues) which recommended that 
employers should be prohibited from requiring genetic profiling as a pre-requisite to 
employment. 154  The Commission noted that this should remain under review, in 
particular with relation to occupational health and safety issues.155 A Joint Statement 
of Concern presented in 2006 to a House of Commons Cross Party Group from forty-
six organisations and individuals called on the Government to legislate against the use 
of test results in employment and insurance. As a consequence, the use of genetic 
profiles by employers is now regulated by the Equality Act 2010, restricting questions 
that employers can ask in pre-employment medical checks. In practice, this means 
that employers can only ask for information that is directly relevant to the applicant's 
ability to carry out the work, or needed to make “reasonable adjustments” to the 
workplace to enable the employment of a particular person.156 
 
3 Critique 
 
The regulatory schemes in Australia and the United Kingdom have advantages and 
disadvantages but do allow the use of genetic profiling as it becomes more 
appropriate, in order to ensure health and safety obligations are met in the 
employment context. Both regimes are complex and ambiguous, involving many 
intersecting pieces of legislation. The “Essentially Yours” Report scrutinised the 
method of regulation in Australia and recommended a number of changes to improve 
the protection currently offered by the legislation surrounding anti-discrimination and 
occupational health and safety.
157
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The complete prohibition such as introduced by GINA in the United States may mean 
that employment use of genetic profiling is limited. The Australian Inquiry concluded 
that a complete prohibition on the use of genetic information in employment is not 
justified, as increased availability is likely to result in an opportunity for more 
balancing of the interests of employers, employees and the public. 158  The 
recommendations for amending the current regulation included the aforementioned 
changes to the DDA to ensure it is clear that an employer is prohibited from 
requesting genetic information from an applicant or an employee unless reasonably 
required for a legitimate purpose. Legal discrimination may arise in situations such as 
when necessary to ensure an employee is able to perform the “inherent requirements” 
of the job or in relation to occupational health and safety issues.159 Allowing the use 
of genetic profiles to meet health and safety obligations could result in practices 
called “victim blaming,” as it may allow an employer to avoid the alteration of the 
workplace or removal of dangerous substances, but rather choose not to employ a 
higher risk individual.
160
 The “Essentially Yours” Report found that in the Health and 
Safety context, the genetic information should only be used in the limited 
circumstances that are subject to the oversight of the Human Genetics Commission of 
Australia.
161
 
 
C Recommendations for New Zealand 
 
Research has indicated that in other jurisdictions it is expected that employers will 
increasingly come under pressure from insurance companies (where employment is 
linked to health, life, or disability insurance) or compensation schemes (directly or 
through the cost of premiums) to use genetic profiles to screen employees.162 New 
Zealand employment law and practices are not the same as in other countries, such as 
the United States and there is less intersection with the insurance issues. Different 
social practices and starting points may result in different sets of implications and 
may call for different policy responses.163 
 
In New Zealand, there have been minimal regulatory responses to genetic profiling in 
the employment context. As outlined in Part III with respect to insurance, New 
Zealand needs to consider the effectiveness of the Human Rights Act 1993 (HRA) 
and the Bill of Rights Act 1990 (BORA) in preventing genetic discrimination in 
employment and whether legislative amendment is necessary to comply with 
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international obligations.164 It is proposed (in Part III) that an amendment to clarify a 
“disability” is necessary. A distinction should be made between pre-symptomatic 
disabilities and the pre-disposition genetic conditions, which may depend on 
environmental conditions and lifestyle choices. Doubts have also been raised as to 
whether the HRA and health and safety legislation will provide adequate protection 
against discrimination in employment.  
 
The relatively infrequent use of genetic profiling currently occurring in New Zealand, 
arguably does not justify enacting specific legislation. It is recommended that New 
Zealand implements an Advisory Body, similar to that recently set up in Australia, to 
consider an appropriate response in a New Zealand context and to supervise and 
advise policy governing the use of genetic profiling in the workplace. The Health and 
Safety (Pike River Implementation) Bill, introduced to Parliament in June 2013, will 
set up WorkSafe New Zealand as a new agency of health and safety (expected to be in 
place by December 2013).
165
 WorkSafe New Zealand is able to establish Advisory 
Groups to provide a “forum for dialogue” and advice, representing the views of 
“Government, employers and employees” to WorkSafe New Zealand on health and 
safety as well as other matters relating to its functions.
166
 It is therefore proposed that 
the establishment of an Advisory Body could come within this new structure.   
 
Appropriate policy should include a requirement that employee autonomy be 
recognised as far as possible, by giving the option of whether to undergo genetic 
profiling or at least enable participation in any decisions made by being fully 
informed about the relevance of the condition in the employment context.167 However 
the exercising of employee autonomy may be restricted due to the affect on third 
parties or the potential to result in a decision to accept dangerous work that is not in 
the best health interests of the employee.  
 
It is also necessary to consider the stigma, particularly with respect to genetic 
information involving sensitive personal issues that may affect family members 
beyond the employment relationship.
168
 Prior to the carrying out of genetic profiling 
the minimum expectation would need to be that the employer seek to alter work 
procedures in order to eliminate any possible risks linked to genetic diseases. Pre-test 
counselling would need to be given so that employees are provided with an 
explanation of any available scientific evidence of links between genetic conditions 
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and workplace practices. Independent testing facilities would be required to conduct 
the tests. Post-test counselling would be necessary with a full explanation of the 
results and their implications, including a range of options for the employee to 
consider should the tests reveal problems in the particular work place.169 
 
The issues that have arisen in the employment context and an analysis of the different 
approaches that have been taken to address the concerns about discrimination have 
been presented in this section. The conclusion is that the current legislation is 
ambiguous and unclear due to the failure to adequately address the concerns raised for 
the future of genetic profiling in employment. Recommendations stop short of an 
overall legislative provision relating to all the issues raised but include amendments 
and a proposal that an Advisory Body be established by WorkSafe New Zealand, with 
a role in monitoring employment changes and providing advice on the issue of genetic 
profiling in the context of employment. 
 
V Genetic Databases 
 
Human tissue samples are stored in various places in New Zealand such as District 
Health Boards, pathology laboratories, universities, commercial enterprises, 
diagnostic laboratories and private research collections.170 These samples can be used 
to perform genetic profiling and thus obtain information about the donor. That 
information is then stored in genetic databases (sometimes referred to as DNA Banks), 
which are used in both the public and the private sector for clinical, research and 
public health purposes (along with other nonrelated functions such as identification of 
the remains of soldiers, prosecution through DNA fingerprinting of suspects and 
paternity disputes).171  
 
Concerns have been raised about the relatively uncontrolled access to genetic 
information. A common fear, addressed above, is that access to such information 
could potentially lead to discrimination by insurance companies and employers. 
However, it is also of concern to some people that parts of their “unique genetic 
makeup” may be used for purposes other than that for which the original consent was 
given.172 In a New Zealand context, Maori and Pacific peoples may have specific 
interests in genetic information and the implications for whakapapa or genealogy.173 
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Public health and research communities would benefit from using existing tissue 
samples to create new genetic databases, such as seen in the United Kingdom 
Biobank. Between 2006 and 2010, the Biobank recruited 500 000 volunteers to 
provide samples and other medical information which was made available to public 
and private researchers providing that the research met scientific and ethical approval 
and was in the public interest.174 The aim was to improve the health of the United 
Kingdom public by integrating findings into the health care system and encouraging 
and advancing research directed towards locating susceptibility genes for certain 
diseases. 175  Results are available in a database accessible to all researchers, 
pharmaceutical and other health based companies (where using it for an approved 
purpose) but not insurers or employers.176 Relatives, police and lawyers cannot access 
the information unless compelled by the courts. 177  Although the information is 
anonymous, the confidentiality is contentious as genetic information is arguably in 
itself a personal identifier.178  
 
Using previously stored samples derived from genetic profiling (or through other 
measures) is another method for providing samples to researchers. The problem 
identified in this situation is that, due to new and future technologies, the tissue may 
be used for purposes without the consent of the person who provided the sample.179 
The law and policy must balance the public interest in using these samples against the 
privacy and autonomy of the individual. There is a large public interest in researchers 
having the scientific freedom to access genetic information gathered from stored 
samples to improve health and prevent diseases. The public interest argument must be 
balanced against the reality that, due to inequalities in access to health care, those able 
to take advantage of the treatment and procedures resulting from the research may not 
be the same group that contributed. Other potential problems and controversial 
aspects of genetic databases that are relevant include the privacy and autonomy of 
individuals and public confidence that safeguards will protect any information that 
does arise from the testing of stored samples. Issues similar to those identified earlier 
in this paper, including discrimination in insurance and employment, along with 
stigmatisation as well as concerns about commercialisation.
 180
 
 
Although genetic databases have the possibility of being a useful tool for catching 
criminals, there is a danger of this being inconsistent with the presumption of 
innocence that exists in the criminal justice system, a risk of false accusations and 
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possible intrusion into the privacy of relatives of suspects due to the familial nature of 
DNA.
181
 Use of genetic databases for criminal purposes therefore requires strict 
quality control and assurance measures.182 Given the scope of this paper, analysis is 
limited to the regulation of samples and information derived from genetic profiling of 
those samples, when being used for research. 
 
A New Zealand Law 
 
The Code of Health and Disability Services Consumers Rights 1996 (the Code), as it 
applies to health consumers and researchers, is of relevance in this context. Right 7(9) 
provides that a decision may be made about the return or disposal of a sample and 
Right 7(10) provides that no sample may be stored for use other than with the prior 
informed consent of the consumer or for the purposes of research approved by the 
Ethics Committee.183 Therefore data can be used where there is no consent in some 
circumstances, in contrast to the former Code which required informed consent in all 
circumstances. This was introduced because it may be contrary to the public interest if 
too strict.184  
 
The Code also interacts with an exception in the Health Information Privacy Code 
1994 (HIPC), established under the Privacy Act 1993, which allows health 
information to be used without consent, if the information is to be used for research 
purposes.185 Approval by an ethics committee may be required and publication is not 
permitted in a form that could reasonably be expected to identify the individual 
concerned. The Hazardous Substances and New Organisms Act 1996 amended the 
Health Act 1956, s 121 to allow regulations made under the Act to apply to both 
health information and specimens, defined as “a bodily sample or tissue sample taken 
from a person”.186 Given the complexity of the law, the Ministry of Health undertook 
consultation and a review, adopting the Guidelines for the Use of Human Tissue for 
Future Unspecified Research Purposes 2007, to support researchers. These guidelines 
require that consent to the collection of a sample must be distinct and separate from 
consent provided to the future unspecified use.
187
 
 
The Human Tissue Act 1964 was reviewed by the Ministry of Health in 2005 and 
replaced by the Human Tissue Act 2008 after identifying a number of Act 
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shortcomings. Among others, this included the need to clarify obligations and 
procedures in relation to “historical tissue collections”.
188
 The former Human Tissue 
Act required the person lawfully in possession of the body to establish that there is no 
objection to the use of tissue from a deceased person.189 The 2008 Act provides that 
consent is required to use human tissue collected from a living person for a 
“secondary purpose” after that person’s death.190 However, informed consent is not 
required where analysis has received Ethics Committee approval.
191
 
 
Amendment to the HIPC was made in 2013 to improve “legal protections” around the 
bloodspot sample of newborn babies, collected as part of the National Newborn 
Metabolic Screening Programme. 192  The Privacy Commissioner has raised the 
concern that the development of DNA technologies means requests to use these 
samples as part of a national DNA database are a possibility.193  The amendment 
therefore restricts how information derived from the samples can be used.194 
 
The Operational Standard for Ethics Committees 2006 provides for the protection of 
the interests of the participants in research, safeguarding of the interests of Maori 
culture and promotion of awareness of the ethical principles and practices to the wider 
community. 195  Although the Operational Standard states that research may not 
proceed without obtaining consent from the individual, an exception is allowed where 
it is not practicable or where the Ethics Committees is satisfied that the potential 
public benefit outweighs the need to protect the right of an individual to consent.196 
 
The use of samples without consent may happen in New Zealand where the 
safeguards are met. However the complex framework with interlocking provisions 
from statute and ethical guidelines has been identified as a problem. Calls have been 
made for data collections to fall under stricter regulation and overview, in particular, 
with regard to recognition of Maori and other cultural perspectives.197 
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B Comparative Approaches 
 
The International Declaration on Human Genetic Data art 14 provides for the 
protection of privacy and confidentiality in relation to human genetic data.198 This 
includes an obligation for researchers not to keep such data in a form that allows the 
research participant to be identified “for any longer than is necessary for achieving the 
purposes for which they were collected or subsequently processed”.
199
 Additionally, 
human genetic data should not be disclosed or made accessible to third parties such as 
employers, insurance companies and relatives. An exception exists in limited 
circumstances if it is necessary for “an important public interest reason” provided for 
by domestic law consistent with the international law of human rights, or with the 
“prior, free, informed and express consent” of the persons concerned.200 Article 17 
provides that some “stored biological samples” may be used to produce human 
genetic data with the prior, free, informed and express consent of the person 
concerned.
201
 This is subject to an exception for significant “medical, and scientific 
research purposes” which may be used for these purposes where there is ethics 
committee approval.202 
 
The storage and use of samples and information held in DNA data bases in Australia 
is also regulated by a combination of legislation, guidelines and standards including 
the protection of health information in the Privacy Act 1988 (and other state and 
territory legislation), the Human Tissue Act, the Ethical Guidelines in the National 
Statement and the Human Genetics Society of Australasia (HGSC) Guidelines for 
Human DNA Banking. The Privacy Act protects an individual’s personal information 
and the right to control how it is collected, used and disclosed.203 The legislation 
extends to genetic information and is identified as an important element in regulating 
the operation of research databases.204 The “Essentially Yours” Report in Australia, 
recommended that the Privacy Act be extended to cover genetic samples, rather than 
just the information derived from the samples.205 
 
The various Australian Human Tissue Acts set out the consent procedure.
206
 Tissue 
from a live donor requires verbal consent for specific use, whereas tissue of a 
deceased person may be used for other purposes providing that no objections were 
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expressed during the person’s lifetime and that the next of kin gives consent.207 The 
National Health and Medical Research Council National Statement has general 
provisions which are relevant to the operation of databases. Researchers are required 
to ensure the confidentiality and privacy of stored information, research protocols 
must make clear whether the information is to be stored and in what form (coded or 
anonymous) and individuals should be informed about this intention.208 Further, the 
National Statement generally requires consent to the use of human tissue samples, 
genetic material and genetic information in medical research. 209  The “Essentially 
Yours” Inquiry recommended an additional chapter to provide further ethical 
guidance on the operation of human genetic research databases, specifically with 
respect to consent for unspecified future research.210 The Inquiry was of the view that 
this would provide a valuable ethical baseline against which the operation of human 
research genetic databases could be measured.211 
 
The Guidelines for Human DNA Banking mainly address storage of DNA in the 
context of clinical health services but also state that researchers have obligations to 
the families involved in studies.212  Guidelines recommend the establishment of a 
central directory of DNA Banks storing material for both clinical and research 
services, with the register to be maintained by one regional clinical service.213 
 
C Recommendations for New Zealand 
 
Genetic databases often include the samples as well as the information derived from 
them and both are used in close association to facilitate research. Under the current 
law, individual privacy rights cannot be asserted by the individuals who gave the 
samples.
214
 It would be beneficial to incorporate an amendment in the HIPC, as in 
Australia, which currently covers any information given in association with, or 
derived from, body parts or bodily substances, but does provide protection for the 
actual tissue sample from which genetic information may be gathered.  
 
The former Human Tissue Act required no objection to the use of tissue from a 
deceased person during their lifetime. This has been updated in the 2008 Act to reflect 
informed consent and as such is in line with recommendations in the Australian 
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Inquiry.215 The secondary principle is consistent with Right 7(10) of the Code because 
tissue with no informed consent can only be used with approval by an Ethics 
Committee. The Human Tissue Act does not regulate storage, use or transfer of 
samples as part of genetic databases.216 The Australian Inquiry noted the option of the 
addition of new provisions to cover these gaps in the Australian Acts, but came to the 
conclusion that the law relating to genetic samples and information should be dealt 
with by building on health privacy legislation rather than under the Human Tissue 
Acts.217 Although the recent updates to the Human Tissue Act in New Zealand have 
provided a more comprehensive piece of legislation, there are still similar gaps still to 
be addressed.  
 
The Inquiry also investigated the idea of subjecting the human genetic research 
databases to a licensing or registration regime. A licensing regime would require all 
research databases to obtain a licence to operate, or the alternative “light touch” 
approach would be to implement a system of registration.
218
 This approach would 
require the operators to report to the Australian Health Ethics Committee (AHEC) to 
gain approval for research being undertaken, with the AHEC responsible for ensuring 
compliance with the National Statement. Some researchers were concerned about the 
practical limitations of such a reform as it may be costly and ineffective due to the 
“fluid” nature of research and that documentation would require twice as many staff 
and impose an “unsupportable burden” on research.219 The Inquiry was of the belief 
that genetic databases in a research setting were adequately regulated by the existing 
Human Research Ethics Committees but proposed that a registration system would 
provide “greater transparency and accountability” without subjecting the institutions 
to onerous compliance costs.220  
 
Incorporation of a registration regime in New Zealand could be a useful step in 
providing accurate and comprehensive information to the proposed Advisory Body. 
An additional function could be to keep the public informed about the nature of 
research being undertaken and provide an assurance that privacy, legal and ethical 
standards are being met. This would be a means of safeguarding against the negative 
consequences of a lack of transparency such as a general fear or distrust within the 
public about using advancing technologies, which may in turn be detrimental to 
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public health, if it was to limit research resources vital to advancing biomedicine and 
genetic profiling.  
 
VI Disclosure to Relatives 
 
Disclosure of genetic information to relatives may prevent serious or imminent threat 
to their life or health resulting in the issue of defining the responsibility of health 
professionals with respect to the duty to inform relevant members of a patient’s 
family. However this needs to be balanced against the autonomy, confidentiality and 
privacy of the individual that traditionally has been the starting point for regulating 
health information. This discussion is largely underpinned by consideration of genetic 
exceptionalism.
221
 One argument is that genetic information is not sufficiently 
different to other medical information to justify the development of an alternative 
legal framework. The law protects confidentiality with exceptions for certain 
circumstances and further, where a patient poses a risk to another individual the 
courts have accepted that limited disclosures of confidential information may be 
justified in order to avoid that harm.222  It could be argued that the existing law 
surrounding confidentiality already provides a framework for disclosure to be 
permitted if the health of another person is at risk. The absence of a specific statutory 
duty to warn the third party in New Zealand results in an uncertain legal position for a 
doctor who discloses genetic information to the relatives of a patient.223 
 
The shared nature of genetic information, respect for the privacy of persons and 
confidentiality of personal information are recognised in key international instruments. 
The UDHGHR states that “the human genome underlies the fundamental unity of all 
members of the human family” and recognises it in a symbolic sense as the heritage 
of humanity.224 The International Declaration on Human Genetic Data provides that 
genetic information has special status because it is predictive of predispositions, the 
nature of it is familial, it may have cultural significance and it may contain 
information that is not known or significant at the time when samples are collected.225 
Respect for the privacy of persons and the confidentiality of their personal 
information is recognised in the Universal Declaration on Bioethics and Human 
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Rights, stating that such information should not be “used or disclosed for purposes 
other than those for which it was collected or consented to”.
226
 
 
The decision in the United States in Tarasoff v Regents of the University of California 
imposed a duty of a health professional to warn a third party where there was serious 
danger or violence.227 Arguably this could be applied to a situation in which a health 
professional has an obligation to warn a family member of a patient about their risk of 
developing a disease. 228  The United States Courts have been divided on the 
application of this to the genetic context, with the Supreme Court of Florida finding 
that a duty of care was owed to the children of a patient treated for Medullary Thyroid 
Carcinoma in Pate v Threlkel but that the duty was satisfied by warning the patient of 
the risk to relatives.229 The narrow approach to satisfying the duty of care was not 
adopted by the Superior Court of New York in Safer v Pack, which recognised that 
the duty to warn the plaintiff after treating the father for polyposis was separate to the 
relationship that the health professional has with the public and that the duty of care to 
the third party might override the patient’s right to confidentiality. 230 In addition to 
those cases, the Supreme Court of Minnesota, in Molloy v Meier, has held that “a 
physician’s duty regarding genetic testing and diagnosis extended beyond the patient, 
who was a minor with fragile X syndrome, to biological parents who foreseeably may 
be harmed by a breach of that duty.”231 
 
A New Zealand Law 
 
The Health Information Privacy Code (HIPC) 1994 governs the collection, storage 
and access to health information. It is concerned with protecting the privacy of 
individuals and their personal information that is necessary with health care. The 
HIPC applies to health information, a subset of personal information. The HIPC 
defines health information as information about an identifiable individual, which 
includes information about an individual’s health including medical history, 
disabilities and information provided by testing samples.232 The HIPC also recognises 
that there is a public benefit in allowing access to some information for particular 
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purposes and provides in r 10 that consent by an individual is not required for 
disclosure of health information if the health practitioner “believes on reasonable 
grounds that it is either not desirable or not practicable to obtain authorisation from 
the individual” and (until recently) “the disclosure of the information is necessary to 
prevent or lessen a serious and imminent threat to public safety or the life or health of 
the individual concerned or another individual.” 233  In April 2013 the HIPC was 
amended in accordance with the Privacy Amendment Act 2013, removing the 
requirement of “and imminent,” in order to make the decision on whether to disclose 
information easier.234 Serious threat is defined in the Privacy Act 2013 as having 
regard to “the likelihood of the threat being realised,” the “severity of the 
consequences” and “the time at which the threat may be realised.”235 
 
The New Zealand Medical Association Code of Ethics requires medical practitioners 
to “keep in confidence information derived from a patient” and this can only be 
breached where the law requires otherwise.
236
 The limits to confidentiality between a 
doctor and patient, with regard to human immunodeficiency virus (HIV) patients, 
recognised by New Zealand Medical Association protocols, could arguably be 
extended to genetic diseases.
237
 New Zealand case law on medical confidentiality 
determining whether a breach has occurred includes questions such as whether there 
was an imminent risk of harm to the third party.238 The test developed by the courts 
requires that the risk be major (an immediate danger to the life of the third party) and 
that this belief must be fairly and reasonably held.239 It is therefore possible that if a 
health professional disclosed genetic information about a relative of a patient, the 
public interest exception could be used as a defence.240 Whether or not there is a legal 
duty to warn a third party in common law about a genetic disease is likely to depend 
on proximity and likelihood (Anns test).
241
 This may be covered by the Accident 
Compensation Scheme, avoiding civil proceedings against the health professional.242 
However, the complexity of the interaction with the ACC means that analysis is 
beyond the scope of this paper. 
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The Privacy Commissioner conducted a review of the HIPC and concluded that 
disclosure to at-risk relatives can be made under the existing rule.
243
 This means that 
the patient would have to be informed during pre test counselling that results may be 
disclosed to relatives.244 Health professionals would be required to have a plan should 
disclosure be necessary and ensure intentions are made clear during informed consent 
discussions and pre test counselling.245 
 
The Medical Council of New Zealand provides guidance for best practice, outlining 
the expectation that health professionals should treat all information as “confidential 
and sensitive”, noting the exception to be found in r 10 of the HIPC.
246
 The Council 
has also proposed ethical considerations to aid desirable and proper disclosure. 247 
Further, health professionals should limit the information that is disclosed to only that 
which is necessary in the circumstances, keep comprehensive records and the involve 
colleagues in the making of decisions.248 The HIPC does not impose a duty to contact 
the relatives at risk and disclose the information. The decision is discretionary and 
should be on the basis of whether it is a “matter of good practice for the health 
professional to first communicate his or her intention to do so to the patient” giving 
due consideration to the law and ethics involved.
249
  
 
B Comparative Approaches 
 
There are various approaches comparative approaches including enacting legislation, 
allowing the law to develop on a case by case basis as issues come before the courts 
or regulating by an express or implied contractual provision to the effect that the 
patient agrees to share genetic information with family members.250 
 
A communitarian or medical model of genetic information was proposed by 
Guidelines in a Report of the Cancer Genetics Ethics Committee of the Anti-Cancer 
Council of Victoria, endorsed by the Australia National Health and Medical Research 
Council in 1999. This proposes that genetic information needs to be treated separately 
from other kinds of medical information for the purpose of confidentiality because it 
is inherently familial in nature, setting aside the traditional presumption that the 
confidential status of that information be respected. 251  The Report notes a shift 
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towards institutions looking after genetic information as the wider community 
representatives.
252
 The Guidelines would allow non-consensual disclosure, although 
this should only occur following attempts to persuade the patient to voluntarily 
disclose information to their relatives.253 This approach envisages a proactive role for 
doctors. The implications of this model would be that people would not have a right 
to control their genetic information or the use of tissue taken for genetic profiling and 
that health professionals would be expected to impart information contrary to the 
traditional obligation of maintaining patient confidentiality; a model based on 
community and familial obligations.254 
 
Although a duty to warn has not been recognised by Australian courts to date, the 
1999 case of BT v Oei in the NSW Australia Supreme Court held that a duty of care 
could be owed to a third party where they were at risk of contracting HIV. 255 
However the duty could be discharged through the provision of appropriate advice to 
the patient (not to the third party directly) to get tested for HIV.
256
 The Australian 
Law Reform Commission in 2003 recommended the amendment of the Privacy Act 
“to permit a health professional to disclose genetic information about his or her 
patient to a genetic relative of that patient where the disclosure is necessary to lessen 
or prevent a serious threat to an individual’s life, health or safety, even where the 
threat is not imminent”. This recommendation was put into effect in 2006, with 
amendments passed to make it discretionary, not obligatory, for health professionals 
to disclose genetic information to “genetic relatives”. A genetic relative has been 
defined as “an individual who is related to the first individual by blood including, but 
not limited to, a sibling, a parent or a descendant of the first individual”. The 
amendments provided for the National Health and Medical Research Council to 
develop guidelines to address circumstances where disclosure to genetic relatives is 
ethically justified or required, and the need for patients to be counselled about the 
disclosure of information. The guidelines came into effect from 15 December 2009, 
following approval by the Privacy Commissioner. 
 
In Australia, the “Essentially Yours” Report recommended that s 6 of the Privacy Act 
1988 (Cth) be amended to extend privacy protection to genetic samples as well as 
genetic information. However, the Report also found that the familial dimension of 
genetic information requires acknowledgment in the Privacy Act, as in the example 
that a doctor be authorised to disclose personal genetic information to a relative in 
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circumstances where disclosure is necessary to lessen or prevent a serious threat to an 
individual’s life, health, or safety.
257
  
 
In the United Kingdom, the Data Protection Act 1988 enables individuals to control 
or be aware of the use and content of personal data. This introduced the idea of 
“sensitive data” into United Kingdom law as data encompassing information 
pertaining to an individual’s physical or medical health or condition and in sch 3, sets 
out the relevant conditions, including a requirement of explicit consent. However s 29 
enables the Secretary of State to make an order to exempt and modify provisions in 
relation to personal data concerning physical or mental health and the disclosure of 
genetic information may fall within these exceptions. 258 The Nuffield Council on 
Bioethics in the United Kingdom found that the Data Protection Act 1998 which 
provides that holders of data have a positive obligation to inform the individuals 
concerned, required further clarification, possibly in the form of secondary legislation 
to ensure that the Act was not extended in this way.
259
 
 
A legal model based on the patient’s right to privacy and non discrimination is the 
opposite approach, which has been adopted in the United States in 2008 with GINA 
and was also present in the 1998 Genetic Privacy Non-Discrimination Bill which 
subsequently lapsed. This approach is based on autonomy and self-determination and 
would require the authorisation of the individual before families could be notified.260  
 
C Recommendations for New Zealand 
 
Health professionals in New Zealand can disclose a patient’s genetic information to 
family members at any time providing that the patient has given consent. If the patient 
does not consent, the HIPC enables health professionals to make disclosures in 
limited circumstances. Consistent with Tarasoff v Regents of the University of 
California, the HIPC allows exceptions to the usually strong policy against disclosure 
in the case of a “serious and imminent threat” to the public or to a third party where 
the health professional is able to avoid that harm. It is unclear in New Zealand 
whether the threat of predispositions would fall under this exception. Future case law 
will help define the limits of the HIPC and the circumstances in which there will be a 
duty to warn patients and relatives of the risks associated with unfavourable genetic 
profile results. 
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It is recommended that the HIPC be amended to specifically address genetic 
information including the clarification of circumstances in which genetic information 
should be disclosed to other family members. When balancing the public interest in 
disclosure against the public interest in maintaining confidentiality, considerations 
include the existence of a cure or treatment for the condition, the likelihood of harm 
to relatives and the degree of severity.261 The courts in the United States decisions did 
not address a number of the factors which will likely be critical in the future, such as 
the accuracy of the test performed and the ability of the doctor to interpret the results. 
A balancing approach is advocated, incorporating into the proposed amendments to 
the HIPC in New Zealand. This includes balancing the severity of the disease, the 
availability of treatment, the reliability of the test, the ability of the health professional 
to interpret the issues relevant to the test and the protections provided against 
discrimination.262 The Advisory Body could have a role in the development of policy, 
to assist the Privacy Commissioner in providing guidelines for health practitioners as 
to their duty in this complex area, with further review as the technology develops and 
the uses of genetic profiling expand.  
 
VII Pharmacogenetics 
 
Pharmacogenetic testing is the subset of genetic profiling that analyses drug response. 
It has arisen through the study of individual DNA variation, identifying variants at 
multiple gene loci affecting drug response. Developments in technologies, such as the 
Polymerase Chain Reaction to amplify DNA and the advances in whole genome 
sequencing techniques that led to the sequencing of the entire human genome in 2001 
have been catalysts in the progress that has occurred in this area of genetic 
profiling.263 It is envisaged that the potential benefits of pharmacogenetic testing are 
likely to lead to personalised medicine becoming a central component of health care.  
 
Adverse reactions to medication are a significant health issue as evidenced by 
statistics from the United States suggesting over two million hospitalised patients 
from adverse drug reactions in one year.264 The use of pharmacogenetics to reduce 
adverse reactions to drugs would be a positive step towards increased drug efficacy by 
enabling drug therapy to be based on personal genotype. This in turn is likely to 
reduce the time and cost of developing new drugs and also enable the New Zealand 
Pharmaceutical Management Agency (PHARMAC) to more efficiently subsidise 
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drugs on the basis of their likelihood of working for that individual.265  Given the 
advantages of pharmacogenetic testing and the likely increased role, it is very relevant, 
within the context of this paper, to consider the ethical, social, legal and policy 
implications that arise. 
 
Although many of the considerations are similar to those for other uses made of 
genetic profiling, there is debate about whether similar safeguards should also apply 
to pharmacogenetics.266 It is argued that unlike testing for the inheritance of disease 
associated genes, pharmacogenetic tests do not predict risk of disease and should 
therefore not be subject to the regulatory requirements that apply to genetic profiling 
for mutations associated with diseases as such standards could hinder the integration 
of pharmacogenetics into clinical practice.267  
 
Alternatively, pharmacogenetic testing may affect a patient’s outlook on life and as 
the information has the potential to be misused, there is a need to define professional 
protocols for informing the patient of the risks and benefits, obtain prior consent and 
provide assurance to the patient that adequate measures have been taken to ensure the 
privacy of the test results.
268
 Failure to take these steps may affect acceptance and 
integration of pharmacogenetic testing into health practice.269  
 
Where a pharmaceutical company is sponsoring a clinical drug trial, it is routine for 
the DNA samples to be retained, with an assurance that samples will be destroyed at 
the request of the participants.
270
 The complex arrangements with third party 
corporate bio-banks and the fact that pharmaceutical company genetic databases are 
not subject to the same regulatory mechanisms as public genetic databases mean that 
there is no guarantee that samples are actually destroyed.
271
 Another question arises as 
to whether voluntary consent to retaining samples is realistic, where non-consenting 
may restrict access to a new medicine.272 The result is that the patient’s autonomy to 
decide what happens with their tissue samples is compromised as they may be 
coerced in order to receive a potentially beneficial drug.273 Privacy issues in relation 
to research data also arise but there are various levels of protection, including coding 
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and anonymised samples that could be legislated for, to ensure privacy of the 
participating individuals.
274
 
 
Pharmaceutical tests have less relevance to family members as they predict responses 
to medicines as opposed to disease susceptibility, as stated earlier. The emerging issue 
of ancillary information recovered by these tests may challenge this view and raise 
similar issues with disclosure.
275
  The likelihood that pharmacogenetic information 
would reveal serious or imminent health consequences for family members, although 
small compared to other types of genetic information, is still possible as ancillary 
health information in the future and that means there may be cases where the 
Advisory Body is invoked in relation to pharmacogenetic testing.276 
 
Issues around stigmitisation are also relevant, including the labelling of responders 
and non-responders, with financial consequences and the potential to result in 
insurance and employment discrimination.
277
 There are concerns that stratification of 
the population according to disease and drug response genotypes will lead to 
inequities in drug development efforts and resource allocation.278  
 
It is unclear whether pharmacogenetics will increase or decrease the cost for 
medicines. Although it may enable medicines to be developed more quickly at less 
cost and regulatory approval could be granted sooner, fragmentation of the market 
may lead to reduced profits for pharmaceutical companies, driving up the costs of 
medicines.
279
 Another issue is that pharmacogenetic data may influence the resource 
allocation of PHARMAC in New Zealand, in that cost effectiveness analysis may 
favour treatment for a group with a higher chance of responding to a medicine.280 
  
A number of statutory and non-statutory mechanisms have been identified by which 
genetic profiling in general can be regulated, including changes to the HRA, the role 
of the Insurance and Saving Ombudsman and the development of policies to assist 
employers and health practitioners in making decisions. These considerations are 
equally relevant in the context of pharmacogenetic testing and it is recommended that 
the proposed Advisory Body be involved.   
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VIII Embracing the Challenges 
 
New Zealand currently relies on an assortment of related legislation, regulations, 
ethical guidelines and policies to govern genetic profiling, with a number of aspects 
lacking in clarity. Analysis of the current legislation results in the conclusion that it is 
not illegal to discriminate on the basis of genetic information. This is seen as 
inadequate, suggesting that the law is lagging behind the rapid advances associated 
with genetic profiling technology. The potential benefits for new technologies to 
support significant improvements to public health may be limited by public 
confidence in the safeguards provided by the current regulatory framework. There are 
many ambiguities for individuals accessing genetic profiling technology, such as 
through employment, insurance or other privacy implications, that may lead to 
undesirable implications for people.  
 
In seeking an appropriate legal response to advances in genetic profiling technology, 
it is essential that laws are informed by ethical debate and reflect as largely as 
possible common New Zealand societal values.281 The major challenge is to find an 
approach that meets the dual requirement of encouraging innovative research in the 
field of genetics along with practice that best meets public needs and creating a legal 
framework that supports an environment of trust and confidence within acceptable 
ethical boundaries, for the use of all technologies. 
 
The development of an Advisory Body to oversee the implications of the use of 
genetic profiling, as discussed throughout this paper, is seen an alternative to 
implementing an overarching piece of legislation governing all of these areas. This 
would enhance public confidence by increasing the awareness of all stakeholders 
(including patients, employers, employees, the insurance industry and researchers) 
with regard to the legal and ethical obligations.  
 
Other changes have been recommended to deal with specific gaps that have been 
identified by this paper. A range of safeguards and improved policies are 
recommended for the use of genetic information by the insurance industry. This 
should be aimed at ensuring that genetic information is used in a scientifically reliable 
and acceptable manner. The ISO, with the assistance of the Advisory Body, should be 
responsible for ensuring procedures are fair and justified, supported by an appropriate 
and accessible system for complaints, along with undertaking a role of providing 
education and training to the industry.  
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Employers should only gather and use genetic information in exceptional 
circumstances, for example, where this is necessary to protect the health and safety of 
workers or a third party, and the action should comply with the stringent standards 
developed by the proposed Advisory Body. This paper has recommended changes to 
legislation in order to close the current gaps, including an amendment to the disability 
definition in relation to discrimination in employment and insurance, and also an 
amendment to the HIPC to address the particular challenges of human genetic 
information. This should include acknowledgment of the familial nature of genetic 
information, as in the example of a health professional being authorised to disclose 
personal genetic information to a genetic relative in circumstances where disclosure is 
necessary to lessen or prevent a serious threat to an individual’s life, health, or safety. 
In order to assist an effective nation-wide approach to sharing DNA information, it is 
recommended that the New Zealand Government develop a registration system with 
respect to the collection, use, storage and destruction of DNA (including the genetic 
profiles created from the DNA). 
 
The main recommendation of this paper is the establishment of an independent body 
similar to the Human Genetics Commission of Australia, in order to provide advice to 
the Government as the use of genetic profiling technologies increases in New Zealand 
and to help develop policies which would assist relevant industries such as those 
involved in employment, insurance and research. Such an Advisory Body could also 
have an educative role to promote community awareness in response to emerging 
issues. 
 
IX Conclusion 
 
The increased use and availability is likely to impact on the range and complexity of 
the issues surrounding genetic profiling. This paper has identified areas where 
concerns are likely to arise and has attempted to address those with a number of key 
recommendations. The emphasis is on the need to support access and encourage the 
use of genetic profiling technologies to help improve public health in New Zealand 
and to promote ongoing research and advancement of such technologies. This can 
only be made possible by ensuring that the public can have confidence that safeguards 
will adequately protect from the unwanted consequences of possible misinterpretation 
or misuse of genetic information.  
 
The paper concludes that the option of a comprehensive piece of legislation 
combining the issues that arise from genetic profiling such as discrimination in 
insurance, implications for employment, unacceptable use of genetic databases and 
the duty to disclose information to relatives, under the same umbrella, cannot be 
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justified at this time. The introduction of an Advisory Body is proposed to monitor the 
positions being taken by other jurisdictions and to consider the appropriateness in a 
New Zealand context. 
 
The current moratorium in the insurance industry may be seen to provide sufficient 
safeguards against the risks of stigmatisation but could result in a disincentive as it 
may prevent people taking advantage of the technology available, due to such 
possibilities as higher premiums or ineligibility for insurance. Allowing insurance 
companies to request genetic profiling under current human rights legislation (by 
including genetic discrimination as a prohibited ground), expanding the role of the 
ISO and the introduction of the Advisory Body to monitor discrimination, may 
resolve some of the complex and controversial issues. 
 
The ambiguities of the law safeguarding discrimination in employment have been 
discussed, with recommendations made to clarify the position of the HRA with 
respect to genetic information, including an Advisory Body role in the development 
of policies. Employers should continue to be required to alter work place practice in 
order to provide a safer environment, where possible. The policies should emphasise 
employee autonomy and the familial implications of genetic profiling as far as 
possible, while allowing for restrictions where third parties, such as other employees, 
are affected. Employers should also be responsible for providing relevant genetic 
counselling for an employee.  
 
Genetic databases should be subject to a registration regime that is under the authority 
of the Advisory Body, to enable comprehensive information to be gathered. Under 
this proposal, the Advisory Body would be responsible for using this information to 
monitor and ensure that all legal and ethical standards are maintained, as well as 
having a role in informing the public about procedures being followed in current 
research. This would be a useful way of encouraging increased use of genetic 
profiling technology and further research, as it would safeguard against possible 
public fears surrounding the misuse of genetic information.  
 
The duty of health professionals to inform the relatives of a patient of an unfavourable 
genetic profile is unclear in New Zealand. Although the HIPC enables disclosure in 
cases of serious and imminent threat to a third party, the nature of genetic information 
means that the risk factor will often be unclear. It is therefore recommended that the 
HIPC be amended to clarify the appropriate circumstances for revealing genetic 
information to relatives, weighing the seriousness of the disease and the availability of 
treatment against conflicting issues, such as the protection against discrimination and 
the public expectation that health professionals maintain confidential relationships. 
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The proposed Advisory Body could assist the Privacy Commissioner in both 
developing and reviewing policy, as the uses of genetic profiling technology become 
more wide ranging.   
 
Genetic profiling and pharmacogenetic testing are significant recent advances that 
have the potential to change the nature of health care in New Zealand. It is important 
that the public are engaged and aware of implications for individuals and their 
relatives that may arise from the use of this technology in the context of insurance, 
employment and research, along with other issues not yet considered. The 
introduction of an Advisory Body is one way of monitoring compliance with the law. 
The Advisory Body could have a role in developing policies to assist with the 
complex issues, thus providing adequate assurance for individuals that they will not 
be disadvantaged when using genetic profiling technology.  
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